Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saline + ketamine refers to a compounded or admixture formulation in which ketamine, a dissociative anesthetic and N-methyl-D-aspartate (NMDA) receptor antagonist, is combined with saline (sterile sodium chloride solution) for administration. This combination is not a unique branded product but rather describes the practice of diluting or dissolving ketamine in saline for intravenous, intramuscular, or sometimes intranasal use. Ketamine acts primarily by blocking NMDA receptors in the brain, leading to anesthesia, analgesia, and dissociative effects. It is FDA-approved as an anesthetic agent but also used off-label for pain management and treatment-resistant depression. Saline serves as an inert vehicle to deliver the active drug. Compounded formulations such as this are not FDA-approved; their safety and efficacy profiles depend on compounding practices[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on saline + ketamine.